Overview

* Neurocrine Q3 2025 net product sales rise 28% yr/yr to $790 mln

* Adjusted EPS for Q3 2025 beats analysts' expectations

* Adjusted net income for Q3 2025 exceeds analysts' estimates

Outlook

* Neurocrine reaffirms full-year 2025 INGREZZA sales guidance at $2.5 bln to $2.55 bln

* Company expects 2025 GAAP R&D expenses between $1 bln and $1.02 bln

* Neurocrine anticipates 2025 GAAP SG&A expenses to range from $1.14 bln to $1.16 bln

Result Drivers

* INGREZZA DEMAND - INGREZZA sales rose 12% yr/yr due to strong patient demand and record new prescriptions

* CRENESSITY LAUNCH - CRENESSITY's strong launch driven by first-in-class status and 80% reimbursement coverage

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $2.17 $1.58

Adjusted (20

EPS Analysts

)

Q3 EPS $2.04

Q3 Beat $222.10 $160.21

Adjusted mln mln (18

Net Analysts

Income )

Q3 Net $209.50

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Neurocrine Biosciences Inc ( NBIX ) is $170.00, about 12.4% above its October 27 closing price of $148.94

* The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)